- Title
- Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
- Creators
- E. Pujade-Lauraine - Arcagy GinecoK. Fujiwara - Saitama Medical UniversityJ.A. Ledermann - CRUK Lung Cancer Centre of ExcellenceA.M. Oza - Princess Margaret Cancer CentreR.S. Kristeleit - CRUK Lung Cancer Centre of ExcellenceI.L. Ray-Coquard - Centre Léon BérardG.E. Richardson - Cabrini HospitalC. Sessa - Ospedale San Giovanni BellinzonaK. Yonemori - Tokyo National HospitalS. Banerjee - Royal Marsden NHS Foundation TrustA. Leary - Institut Gustave RoussyA.V. Tinker - BC Cancer AgencyK.H. Jung - University of UlsanR. Madry - Poznan University of Medical SciencesS.Y. Park - Swedish InstituteC.K. Anderson - Willamette Valley Cancer Institute and Research CenterF. Zohren - PfizerR. Stewart - PfizerC. Wei - PfizerS.S. Dychter - PfizerB.J. Monk - The US Oncology Network
- Publication Details
- Gynecologic oncology, Vol.154, pp.21-22
- Publisher
- Elsevier Inc
- Identifiers
- 991005968999502656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
Gynecologic oncology, Vol.154, pp.21-22
06/2019
Metrics
1 Record Views